as osteoporosis. Nevertheless, in time, tamoxifenresistant tumours often arise in patients and some of these could benefit from treatment with an antioestrogen, the mechanism of action of which is different from that of tamoxifen. It is important to establish whether other anti-oestrogens function by one or other of the mechanisms suggested for tamoxifen and ICI 164384 or by another novel means. Clearly, a better understanding of the mechanism of hormone antagonists is likely to lead to more efficacious treatment not only of breast cancer but also other endocrine disorders.
The discovery of non-steroidal anti-oestrogens stemmed from observations, dating back more than 50 years, that simple molecules like triphenylchloroethylene have stimulatory effects in classical bioassays of oestrogenic activity, for example the capacity to induce vaginal cornification and uterine growth in immature or ovariectomized rodents. Subsequently, it was shown that addition of a basicether side-chain to the triphenylethylene nucleus produced compounds, like clomiphene and tamoxifen, with anti-fertility activity. Agents of this kind were of great interest because of their potential use as contraceptives, and also for the treatment of malignant and benign diseases dependent on oestrogenic stimulation. Clinical studies failed to confirm useful contraceptive activity, but opened up other therapeutic applications including the treatment of breast cancer.
Clomiphene and tamoxifen were shown to have mixed oestrogen-agonist and antagonist activity. Thus, in the immature-rat-uterus bioassay, tamoxifen stimulates growth, but to a lower maximum extent than the natural hormone 17P-oestradiol; this is a classical partial-agonist effect. Correspondingly, when tamoxifen is administered together with 17P-oestradiol the uterotrophic action of the natural hormone is reduced in a dosedependent manner, demonstrating anti-oestrogenic activity. The maximum antagonist effect in this assay is limited by the intrinsic agonist activity of the particular anti-oestrogen. Thus, complete blockade of oestrogen action cannot be achieved (see [ 1, 21 for reviews of these early studies).
The balance of oestrogenic and anti-oestrogenic activity expressed by the non-steroidal antioestrogens varies widely across species, target organs, cells and genes, depending on which indicator of response is measured [2, 31. In respect of the application of 'Nolvadex' (tamoxifen, ICI 46 474) to breast-cancer treatment, it is legitimate to ask whether the therapeutic efficacy of the drug is in any way limited by the fact that it is a partial agonist. Analysis of clinical experience [4] and animalmodel studies [ 51 suggests that this may be the case, however, a true test of this question can only be made by evaluation of the consequences of complete abrogation of all oestrogen action in patients. This cannot be achieved with any existing treatment, but could be tested if anti-oestrogens completely lacking in oestrogenic activity (i.e. pure anti-oestrogens) were available.
In instituting the search for pure anti-oestrogens, it was clear from previous experience that a novel chemical approach was necessary since all earlier attempts, modelled on existing steroidal or non-steroidal molecules, had met with limited success in reducing agonist activity. The rationale for the synthesis and testing of novel analogues of 17P-oestradiol has been described elsewhere [6] , and led to the discovery of the first series of antioestrogens which satisfy the pharmacological definition of a pure antagonist [7, 81 . Extensive investigation, in this and other laboratories, of the exemplorary compound ICI 164384, a 7a-alkylamide analogue of 17P-oestradio1, has confirmed the following important properties of pure anti-oestrogens (see [9] for review).
In animals, ICI 164 384, unlike tamoxifen, has no oestrogen-like stimulatory activity on the uterus, vagina, mammary gland or hypothalamicpituitary-ovarian axis. Correspondingly, ICI 164 384 blocks the trophic action of exogenous or endogenous oestrogens in a dose-dependent and complete manner. The most instructive demonstration of the difference between pure-and partialagonist anti-oestrogens was provided by the demonstration that co-administration of tamoxifen and ICI 164384 eliminates the trophic action of tamoxifen on the uterus [7] or mammary gland [lo] . The latter observations suggest that pure antioestrogens in vivo will potentially achieve the desired complete hormone ablation.
These pharmacological studies are consistent with the action of all three classes of effectors, that is oestrogens, and pure-and partial-agonist antioestrogens, through a common receptor. This is readily demonstrable in oestrogen-receptorbinding-competition assays, where each ligand displaces ['HI 17B-oestradiol in a concentrationdependent and linear fashion [7] . ICI 164384 has the advantage of a much higher receptor affinity than tamoxifen, which is also reflected in their relative potency as inhibitors of the growth of oestrogen-responsive-human-breast-cancer cells in vitro [7] . The latter studies also revealed that ICI 164384 is much more effective than tamoxifen in reducing the proportion of breast cancer cells which remain capable of DNA synthesis. This is attributed to the residual trophic activity of tamoxifen [ 111. Hy analogy with the animal studies, the blockade by ICI 164384 of the trophic actions of tamoxifen in vitro can be demonstrated using both cell growth [ 1 11 and basement-membrane invasiveness [ 121 as indicators of oestrogen-like activity. Extrapolation of such observations to the clinical setting, implies that the anti-tumour action of pure anti-oestrogens might be enhanced significantly when compared with that of tamoxifen.
Since it became apparent that none of the 7a-alkylamide analogues of oestradiol was of sufficient potency to merit consideration as a drug candidate, further chemical exploration was necessary to identify more potent pure anti-oestrogens. This led us to the compound ICI 182780 [13] 
Introduction
Steroid hormones act via their interaction with intracellular receptors that belong to a general class of regulatory proteins, the 'steroid-receptor superfamily'. This class includes the five 'classical' steroid receptors: oestrogen (ER), androgen (AR), proges- . It quickly became obvious that neither the natural hormones, nor the synthetic reference compounds were perfectly specific for their cognate receptor. While oestradiol bound to a small extent to the PR (2% of progesterone) and the AR (8% of testosterone) in addition to it own ER (loo%), none of the 3-0x0 A-4 steroids had any affinity for the ER.
Among the latter compounds progesterone appeared as having a significant affinity already for the GR, provided a receptor preparation of thymic origin was used. Indeed, liver preparations contain enzymes which metabolize the ligand very quickly, even at 4"C, giving a false impression of selectivity. Among synthetic hormones, R 1881 especially, an androgen of the oestra-4,9,1 l-triene series, displayed a remarkably unspecific binding profile [7] .
These first results already indicate that most receptors, especially AR, PR, GR and MR share common features which allow them to bind some ligands quite unspecifically. This suggests that the steroid receptors may present a common gross shape of
